Human respiratory syncytial virus primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

As the virus is ubiquitous in all parts of the world, avoidance of infection is not possible.

Epidemiologically, a vaccine would be the best answer. Unfortunately, vaccine development has been fraught with spectacular failure and with difficult obstacles. Researchers are working on a live, attenuated vaccine, but at present no vaccine exists. However, Palivizumab (brand name Synagis), a moderately effective prophylactic drug is available for infants at high risk. Palivizumab is a monoclonal antibody directed against RSV proteins. It is given by monthly injections, which are begun just prior to the RSV season and are usually continued for five months. RSV prophylaxis is indicated for infants that are premature or have either cardiac or lung disease.

Template:WH Template:WS